Therapeutic approaches for different stages of MASLD
| Effective treatment† | Improve MASL | Improve/resolution MASH | Improve liver fibrosis/cirrhosis |
|---|---|---|---|
| -Diet and increased physical activity-Bariatric surgery-PPAR receptor agonists: pioglitazone, lanifribranor, saroglitazar-Incretin receptor agonists: liraglutide, semaglutide, tirzepatide-SGLT-2 inhibitors: dapagliflozin, empagliflozin-Thyroid hormone receptor-β agonists: resmetirom | -Diet and increased physical activity-Bariatric surgery-PPAR receptor agonists-Incretin receptor agonists-SGLT-2 inhibitors-Thyroid hormone receptor-β agonists | -Diet and increased physical activity-Bariatric surgery-PPAR receptor agonists-Incretin receptor agonists-Thyroid hormone receptor-β agonists | -Diet and increased physical activity-Bariatric surgery-PPAR receptor agonists-Thyroid hormone receptor-β agonists |
† With the exception of resmetirom, drug treatments are currently considered off-label for MASLD. Some drugs are approved for treatment of MASLD-associated comorbidities such as type 2 diabetes and obesity. MASLD: metabolic dysfunction-associated steatotic liver disease; MASH: metabolic dysfunction-associated steatohepatitis; PPAR: peroxisome proliferator-activated receptors; SGLT-2: sodium-glucose cotransporter 2